Bryan Johnson

Bryan Johnson is an American entrepreneur who moved from payments and deep-tech investing into a public, data-driven longevity experiment. His earlier identity is anchored in Braintree/Venmo, OS Fund, and Kernel: OS Fund says he invested $100M into OS Fund in 2014, founded Kernel in 2016 with another $100M commitment, and previously founded Braintree, sold to PayPal in 2013 for $800M. The University of Chicago profile frames this as a post-Braintree pivot from commerce infrastructure toward “help humanity thrive” ventures in engineered biology, climate/health deep tech, and brain interfaces.

Since 2021, Johnson’s public center of gravity has been project blueprint, a self-experiment intended to measure 70+ organs, quantify biological age, and use an evidence-and-biomarker feedback loop to choose interventions. In the original Project Blueprint post, Johnson described “firing Evening Bryan” from food decisions, shifting decision authority from preference to biomarkers, and treating Blueprint as a “stock ticker” for the current state of anti-aging science, albeit explicitly as an N=1 experiment.

Johnson’s worldview now fuses personal health optimization with the broader dont die frame: death, biological aging, planetary risk, and AI-era existential risk are treated as problems for coordinated measurement, technology, community, and norm formation. His home page presents three pillars: Don’t Die as community, Protocol as freely available information, and Blueprint as interventions/commerce.

Key entities and relationships

  • project blueprint — Johnson’s protocol, self-experiment, product ecosystem, and measurement methodology.
  • dont die — the community/ideology that generalizes his health project into a civilizational slogan.
  • Kernel — neurotechnology company founded by Johnson; relevant to his recurring “what we measure, we improve” thesis.
  • OS Fund — deep-tech fund founded/co-founded by Johnson; part of his post-Braintree capital allocation thesis.
  • Braintree/Venmo — the payments company/acquisition that funded later projects.

Recurring claims in Johnson’s own materials

Johnson claims to be among the most biologically measured people, and his protocol page lists percentile-style outcomes across muscle, fat, bone mineral density, resting heart rate, fertility, blood pressure, vascular function, sleep, grip strength, glucose, and blood-sugar control. These are primary-source self-reports and should be treated as claims requiring context rather than independent clinical validation.

On X/Twitter in May 2026, Johnson’s messaging emphasized sleep, resting heart rate before bed, biomarkers-in-context, sauna experiments, peptide experiments, certified products, and scaling a “female Bryan Johnson” / female-specific protocol via Kate Tolo. This shows that the public project is no longer just a static protocol; it is a daily media feed of experiments, product launches, health claims, and “Don’t Die” norm-setting.

Reading stance

Use Johnson as a high-signal case study in biomarker driven longevity protocols, but keep claims separated into: (1) independently verifiable biography/business facts, (2) Johnson/Blueprint primary-source health claims, and (3) third-party scientific/medical interpretation. His transparency and measurement density are useful; the N=1 design, simultaneous intervention changes, commercial incentives, and reliance on surrogate biomarkers limit generalizability.